Shivalik Rasayan moves to reshape its capital structure

The warrant allotment is split 45.15% to the promoter and 54.85% to non-promoter public-category investors. On a fully diluted basis, the entire preferential issue would add 1,229,990 shares, reducing the ownership of shareholders who held shares before the issue by 7.24% relative, or leaving them with 92.76% of the post-issue share capital, assuming they do not participate.

Preferential allotment breakdown

The company allotted 282,000 equity shares entirely to public-category allottees at Rs 250 per share, raising Rs 7.05 Crores ^[1]. It separately approved 947,990 warrants at Rs 250 per warrant, for an aggregate Rs 23.70 Crores ^[1]. The warrant split is 428,000 to promoter entity Growel Remedies and 519,990 to the two public-category investors ^[1].

• Warrant tranche: promoter 45.15%; non-promoter/public investors 54.85%.
• Combined equity-plus-warrant tranche: promoter 34.80%; non-promoter/public allottees 65.20%.
• At full conversion, the promoter warrants represent approximately 2.52% of the fully diluted share capital; the public-category warrants represent approximately 3.06%.

Pro-forma dilution

The 282,000 equity-share allotment increased issued shares to 16,032,365 ^[1]. Full conversion of the 947,990 warrants would increase this to 16,980,355 shares ^[1].

• Warrant-only dilution: 947,990 additional shares / 16,980,355 fully diluted shares = 5.58%. Shareholders present after the equity allotment but before warrant conversion would collectively fall from 100% to 94.42% of the company.
• Full preferential-issue dilution: Pre-issue shares are derived as 16,032,365 minus 282,000, or 15,750,365 shares. Including both the equity shares and warrants, total new shares are 1,229,990. Therefore, pre-issue shareholders would retain 15,750,365 / 16,980,355 = 92.76%, implying 7.24% relative dilution.

The 7.24% figure is the relevant impact for an existing public shareholder who held shares before the preferential issue and receives neither the new equity shares nor the warrants. The 5.58% figure isolates the incremental dilution from warrant conversion after the 282,000 equity shares have already been issued.

The disclosed board-resolution extracts do not specify any rupee amount or percentage for debt reduction versus API/agrochemical capacity expansion. Therefore, the allocation between these two uses cannot be quantified from the cited resolution.

Proceeds disclosed

• Equity shares: Rs 7.05 Crores raised through 282,000 shares at Rs 250 per share ^[1].
• Warrants: Rs 23.70 Crores of stated aggregate consideration for 947,990 warrants at Rs 250 each ^[1].
• Total stated consideration: approximately Rs 30.75 Crores, derived from the equity allotment and warrant consideration above. This should not be treated as wholly immediate cash proceeds because the warrant conversion/payment mechanics are not specified in the cited extracts.

Leverage alignment

The latest consolidated KPI data shows:

• Debt-to-equity ratio: 0.19x in Q1 FY27 ^[2].
• Total debt: Rs 113.64 Crores ^[3].
• Total equity: Rs 599.10 Crores ^[4].

This is a relatively modest reported leverage ratio, so the issue appears capable of supporting both balance-sheet strengthening and growth investment; however, the available board-resolution text does not establish how much is intended for debt repayment or for the API/agrochemical projects. Any precise split would require the detailed “objects of the issue” section or offer document, rather than the allotment summary currently cited.

Conversion deadline: The 947,990 warrants are convertible into an equivalent number of equity shares, in one or more tranches, within 18 months from the date of allotment ^[5]. The allotment was approved on 14 September 2026 ^[1]; therefore, the outer conversion date is 14 March 2028, derived from the 18-month term and the allotment date.

Under the Regulation 167 framework, the promoter/promoter-group tranche carries the longer lock-in, while securities allotted to non-promoter allottees carry the one-year lock-in. The resultant equity shares from warrant conversion follow the corresponding lock-in treatment. Any pre-preferential shareholding of the allottees, if applicable, is subject to a separate lock-in up to six months from trading approval.

The practical distinction is that conversion must occur by 14 March 2028, but the lock-in period is measured from the applicable trading approval, not from the conversion request date.